Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Atossa Therapeutics, Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 examiners across 5 art units, showing broad examiner distribution with some art-unit overlap.
SAWYER, JENNIFER C is the busiest examiner, with 1 pending matter. The even examiner allocation limits the value of a single examiner-specific playbook, while the art-unit structure may support limited procedural coordination.
Counsel should organize the portfolio around recurring technical issues and art-unit practice, then tailor claim amendments and evidence to each examiner. Consistent disclosure positions may reduce avoidable differences among related responses.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAWYER, JENNIFER C | 1 | 68.4% | -8.2% |
| WORSHAM, JESSICA N | 1 | 56.6% | +56.4% |
| VANNI, GEORGE STEVEN | 1 | 66.8% | +25.2% |
| HILL, MYRON G | 1 | 66.1% | +20.7% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029812 | VIRAL VACCINE COMPOSITIONS FOR INOCULATING A SUBJECT AGAINST A CORONAVIRUS, AN INFLUENZA VIRUS, OR BOTH | GILL, RACHEL B | 86d overdue |
| 18568768 | REMOTE DETECTION OF PATHOGENS | VANNI, GEORGE STEVEN | — |
| 18568769 | COMPOSITIONS AND METHODS TO INCREASE CORONAVIRUS IMMUNE RESPONSE | HILL, MYRON G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029812 | VIRAL VACCINE COMPOSITIONS FOR INOCULATING A SUBJECT AGAINST A CORONAVIRUS, AN INFLUENZA VIRUS, OR BOTH | GILL, RACHEL B | 86d overdue |
| 18859140 | HIGH DOSE ENDOXIFEN FORMULATIONS AND METHODS OF USE | WORSHAM, JESSICA N | — |
| 18568768 | REMOTE DETECTION OF PATHOGENS | VANNI, GEORGE STEVEN | — |
| 18568769 | COMPOSITIONS AND METHODS TO INCREASE CORONAVIRUS IMMUNE RESPONSE | HILL, MYRON G | — |
| 18279577 | ENDOXIFEN FOR TREATMENT OF OVARIAN CANCER | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1691 | 1 |
| 1615 | 1 |
| 1686 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19005858 | ANTI-TUMOR COMPOUNDS AND METHODS OF USE THEREOF AND SYNTHESIS THEREOF | SAWYER, JENNIFER C | 1691 | §103 | Final Rejection | 28d | Pending | Dec 30, 2024 |
| 18859140 | HIGH DOSE ENDOXIFEN FORMULATIONS AND METHODS OF USE | WORSHAM, JESSICA N | 1615 | §102DP | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18568768 | REMOTE DETECTION OF PATHOGENS | VANNI, GEORGE STEVEN | 1686 | §101§103§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18568769 | COMPOSITIONS AND METHODS TO INCREASE CORONAVIRUS IMMUNE RESPONSE | HILL, MYRON G | 1671 | §102§103§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18279577 | ENDOXIFEN FOR TREATMENT OF OVARIAN CANCER | LEE, WILLIAM Y | 1623 | §103 | Non-Final OA | — | Pending | Aug 30, 2023 |
| 18029812 | VIRAL VACCINE COMPOSITIONS FOR INOCULATING A SUBJECT AGAINST A CORONAVIRUS, AN INFLUENZA VIRUS, OR BOTH | GILL, RACHEL B | 1671 | §103§112 | Final Rejection | 86d overdue | Pending | Mar 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAtossa Therapeutics, Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Jennifer C Sawyer has the most, with 1 of Atossa Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
